International pivotal phase III trial of liposomal paclitaxel [EndoTag-1] in patients with triple-negative breast cancer.
Not yet recruiting
Phase of Trial: Phase III
Latest Information Update: 27 May 2013
At a glance
- Drugs Paclitaxel (Primary)
- Indications Breast cancer
- Focus Registrational; Therapeutic Use
- 27 May 2013 This trial is expected to start in the second half of 2014, according to a media release from SynCore Biotechnology and MediGene.
- 27 May 2013 Status changed from planning to not yet recruiting, as reported in a media release from SynCore Biotechnology and MediGene.
- 13 Jul 2012 New trial record